Bionime Corporation Statistics
Bionime Corporation (4737) Stock Statistics & Valuation Metrics
Total Valuation
Bionime Corporation has a market cap or net worth of TWD 4.21B. The enterprise value is TWD 6.52B.
- Market Cap
- TWD 4.21B
- Enterprise Value
- TWD 6.52B
Share Statistics
Bionime Corporation has 77,398,254 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 77,398,254
- Owned by Insiders
- ―
- Owned by Institutions
- 0.10%
Financial Efficiency
Bionime Corporation’s return on equity (ROE) is -0.10 and return on invested capital (ROIC) is -2.94%.
- Return on Equity (ROE)
- -0.10
- Return on Assets (ROA)
- -0.03
- Return on Invested Capital (ROIC)
- -2.94%
- Return on Capital Employed (ROCE)
- -0.05
- Revenue Per Employee
- 1.65M
- Profits Per Employee
- -162.27K
- Employee Count
- 1,111
- Asset Turnover
- 0.32
- Inventory Turnover
- 2.65
Valuation Ratios
The current PE Ratio of Bionime Corporation is -14.22. Bionime Corporation’s PEG ratio is 0.20.
- PE Ratio
- -14.22
- PS Ratio
- 2.58
- PB Ratio
- 2.14
- Price to FCF
- -82.80
- Price to Operating Cash Flow
- 35.72
- PEG Ratio
- 0.20
Income Statement
In the last 12 months, Bionime Corporation had revenue of 1.84B and earned -180.28M in profits. Earnings per share was -2.65.
- Revenue
- 1.84B
- Gross Profit
- 627.81M
- Operating Income
- -197.36M
- Pretax Income
- -249.41M
- Net Income
- -180.28M
- EBITDA
- -15.08M
- Earnings Per Share (EPS)
- -2.65
Cash Flow
In the last 12 months, operating cash flow was 125.88M and capital expenditures -179.36M, giving a free cash flow of -53.49M billion.
- Operating Cash Flow
- 125.88M
- Free Cash Flow
- -53.49M
- Free Cash Flow per Share
- -0.68
Dividends & Yields
Bionime Corporation pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.21%
- Earnings Yield
- -6.35%
Stock Price Statistics
- Beta
- 0.22
- 52-Week Price Change
- -11.27%
- 50-Day Moving Average
- 57.57
- 200-Day Moving Average
- 58.42
- Relative Strength Index (RSI)
- 44.18
- Average Volume (3m)
- 80.40K
Important Dates
Bionime Corporation upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 06, 2026
- Next Earnings Date
- Mar 17, 2027
- Ex-Dividend Date
- ―
Financial Position
Bionime Corporation as a current ratio of 0.75, with Debt / Equity ratio of 175.30%
- Current Ratio
- 0.75
- Quick Ratio
- 0.53
- Debt to Market Cap
- 0.76
- Net Debt to EBITDA
- -174.86
- Interest Coverage Ratio
- -3.04
Taxes
In the past 12 months, Bionime Corporation has paid -70.08M in taxes.
- Income Tax
- -70.08M
- Effective Tax Rate
- 0.28
Enterprise Valuation
Bionime Corporation EV to EBITDA ratio is -43.92, with an EV/FCF ratio of -125.27.
- EV to Sales
- 3.90
- EV to EBITDA
- -43.92
- EV to Free Cash Flow
- -125.27
- EV to Operating Cash Flow
- 53.23
Balance Sheet
Bionime Corporation has TWD 444.78M in cash and marketable securities with TWD 2.66B in debt, giving a net cash position of -TWD 2.21B billion.
- Cash & Marketable Securities
- TWD 444.78M
- Total Debt
- TWD 2.66B
- Net Cash
- -TWD 2.21B
- Net Cash Per Share
- -TWD 28.56
- Tangible Book Value Per Share
- TWD 15.16
Margins
Gross margin is 32.68%, with operating margin of -17.96%, and net profit margin of -16.62%.
- Gross Margin
- 32.68%
- Operating Margin
- -17.96%
- Pretax Margin
- -22.00%
- Net Profit Margin
- -16.62%
- EBITDA Margin
- -8.88%
- EBIT Margin
- -19.34%
Analyst Forecast
The average price target for Bionime Corporation is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -11.64%
- EPS Growth Forecast
- -140.47%
